瑞银发表研究报告,对CRO股份投资评级及目标价表列如下:股份 | 投资评级 | 目标价(港元)药明康德(02359.HK) | 买入 | 171.2元 → 176.5元药明生物(02269.HK) | 买入 | 51.1元药明合联(02268.HK) | 买入 | 89.4元 → 87.4元相关内容《大行》招银国际:美国针对创新药将加征关税 预期对CXO影响有限康龙化成(03759.HK) ...
Source Link瑞银发表研究报告,对CRO股份投资评级及目标价表列如下:股份 | 投资评级 | 目标价(港元)药明康德(02359.HK) | 买入 | 171.2元 → 176.5元药明生物(02269.HK) | 买入 | 51.1元药明合联(02268.HK) | 买入 | 89.4元 → 87.4元相关内容《大行》招银国际:美国针对创新药将加征关税 预期对CXO影响有限康龙化成(03759.HK) ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.